A recent study published in Advanced Nanobiomed Research explores a new method for delivering epigallocatechin gallate (EGCG), a bioactive compound found in green tea, using polyurethane nanocapsules.
This controlled and targeted drug delivery approach is designed for trauma care, particularly for managing traumatic brain injuries (TBIs) caused by explosions, which account for nearly 79 % of combat-related injuries.
Image Credit: Gorodenkoff/Shutterstock.com
Background
TBIs require a comprehensive treatment strategy that extends beyond immediate care to long-term recovery. Traditionally, steroids have been used in TBI management, but their effectiveness varies, and they can have significant side effects.
As an alternative, EGCG has gained attention for its neuroprotective properties, including its ability to reduce cell death, support new blood vessel growth, and regulate inflammation.
Previous research has shown that EGCG can improve recovery in animal models, making it a promising candidate for TBI treatment when delivered directly to the injury site. However, existing delivery methods only provide short-term release, limiting EGCG’s therapeutic impact.
To overcome this challenge, researchers explored the potential of polyurethane nanocapsules to create a sustained delivery system for EGCG in trauma care.
The Current Study
The researchers focused on developing and analyzing polyurethane nanocapsules to effectively encapsulate and deliver EGCG. The nanocapsules were created through a specialized emulsion process to ensure stability and efficiency.
Their size distribution and surface charge were measured using dynamic light scattering (DLS), while transmission electron microscopy (TEM) was used to examine their structure.
Fourier Transform Infrared Spectroscopy (FTIR) was performed to confirm the successful encapsulation of EGCG without altering its chemical properties. In vitro studies tested how EGCG was released from the nanocapsules, using both passive diffusion and external stimuli, such as ultrasound, to control drug release rates.
The study also evaluated the initial burst release of the drug followed by sustained delivery, assessing its potential for treating TBIs and associated complications.
Results and Discussion
The results confirmed that the polyurethane nanocapsules effectively encapsulated EGCG while preserving its molecular structure, as verified by FTIR spectroscopy. Initial release tests showed that about 20 % of the drug was released within the first week, followed by a slow, controlled release.
The ability to adjust drug release using ultrasound provides a flexible treatment option, allowing for customized dosing based on patient needs in trauma settings.
Sustained release is critical for TBI treatment, as secondary injury processes like neuroinflammation and oxidative stress continue long after the initial trauma. The study highlights that EGCG, through its various mechanisms, could help reduce these secondary effects, potentially improving recovery outcomes.
The research suggests that polyurethane nanocapsules could enhance the effectiveness of TBI treatments by ensuring a steady presence of EGCG at the injury site and offering a controlled release system that adapts to changing therapeutic needs.
Future studies will need to investigate how these nanocapsules interact with biological systems in live models and their potential impact on clinical outcomes.
What Could This Mean for TBI Treatment?
This research opens up new possibilities for using nanotechnology in trauma care. Polyurethane nanocapsules could provide a more effective way to deliver neuroprotective compounds like EGCG, ensuring sustained release and precise dosing.
If further studies confirm their benefits, these nanocapsules could be integrated into future treatments for TBIs, improving patient outcomes in combat settings and other high-risk environments.
Continued research in this area may lead to broader applications for targeted drug delivery in neurotrauma and beyond.
Journal Reference
Ale T., et al. (2025). Polyurethane Nanocapsules Incorporating Epigallocatechin Gallate, A Green Tea Extract. Advanced NanoBiomed Research, 2400204. DOI: 10.1002/anbr.202400204, https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/anbr.202400204